The Cannabis Industry Fought for Medical Access. Why Is It Silent Now?

Parts of the licensed cannabis industry are celebrating the federal hemp ban coming this November.

The logic is straightforward: eliminate intoxicating hemp products, remove an unfair competitor, and push consumers back into licensed dispensaries.

But buried inside the ban is a much larger consequence.

It could eliminate the exact full-spectrum, non-intoxicating therapeutic hemp formulations that helped prove cannabis has legitimate medical value.

That should force the entire industry to reconsider what it stands for.

For decades, cannabis advocates asked America to look beyond prohibition and recognize a basic truth: this plant has therapeutic properties. Those properties deserve to be researched, understood, protected, and made accessible to the people whose lives are improved by them.

Many of us have watched cannabis help a parent, a child, a friend, or another loved one. Those stories changed public opinion. They helped dismantle decades of misinformation and gave lawmakers the political space to create medical programs and, eventually, adult-use markets.

Medical access was not a side argument.

It was the foundation of the movement.

This is not a defense of intoxicating synthetic cannabinoids sold outside regulated markets. It is not an argument against testing, age restrictions, responsible labeling, or enforcement.

It is an argument for precision.

According to Paige Figi, lawmakers intended to target intoxicating and manipulated hemp products. Instead, two members of Congress inserted language into a massive spending bill without a hearing, public debate, or the normal legislative process.

The result was language broad enough to potentially wipe out nearly the entire therapeutic hemp category.

What should have been handled with a scalpel was done with a sledgehammer.

The people hit hardest will not be the companies producing intoxicating products designed to exploit regulatory gaps.

They will be families using non-intoxicating, full-spectrum therapeutic formulations for epilepsy, seizures, inflammation, and other serious conditions.

Paige estimates that approximately 45 million Americans use CBD or therapeutic hemp products every day. These are not occasional consumers chasing a trend. Many have incorporated these products into their daily medical routines, sometimes after conventional options failed them.

For 16 years, Paige Figi and her family helped bring therapeutic hemp into the national conversation through Charlotte's story.

Charlotte did more than introduce America to CBD. Her experience forced the country to reconsider what it believed about cannabis. It showed parents, physicians, lawmakers, and the public that compounds from the plant could produce meaningful therapeutic results.

Her story helped create a movement.

Now, the specific full-spectrum formulation behind that movement is at risk of disappearing.

Paige described the cruelty of that reversal:

"It almost feels worse to have brought this solution to the public, created a movement unintentionally, and then have it stripped away. It would almost be easier for people to have never known there was a solution than to have their child experience sixteen years of success and then have that pulled away for no reason."

That is the human reality hidden beneath the policy debate.

Imagine exhausting every available option for your child. Imagine finally finding something that reduces their seizures, stabilizes their condition, or gives your family some quality of life.

Then imagine losing that exact product.

Not because it was proven unsafe.

Not because it stopped working.

Not because a better alternative became available.

Because Congress used language intended for one product category and swept another category away with it.

The cannabis industry does not need to agree on every commercial or regulatory issue. Licensed operators and therapeutic hemp advocates will sometimes have conflicting objectives. That is inevitable in a market shaped by federal prohibition, state-led legalization, inconsistent regulations, and separate medical and adult-use systems.

But this principle should not be controversial:

Patients should not lose access to legitimate therapeutic products because lawmakers failed to distinguish them from intoxicating ones.

The industry cannot claim the plant has medical value while remaining silent as therapeutic access is stripped away.

It cannot demand science-based cannabis policy while accepting a ban that ignores the scientific and practical differences between these products.

And it cannot celebrate progress toward legalization while abandoning the families whose stories helped make that progress possible.

The cannabis industry fought for decades to prove this plant has medical value.

Now it must defend the people who rely on it.

Before 45 million Americans are left searching for substitutes, crossing state lines, entering dispensaries that may not carry what they need, or losing access altogether, licensed cannabis operators have an obligation to speak.

In this episode, Paige Figi explains what Congress misunderstood, why the cannabis industry's silence is so consequential, how financial interests distorted the debate, and what must happen before the federal hemp ban takes effect this November.